首页 | 本学科首页   官方微博 | 高级检索  
     

suPAR与多发性骨髓瘤预后关系的研究进展
引用本文:黄艳平. suPAR与多发性骨髓瘤预后关系的研究进展[J]. 医学综述, 2013, 19(9): 1584-1586
作者姓名:黄艳平
作者单位:黄艳平 (广西柳州市人民医院血液科,广西,柳州,545006);
基金项目:广西壮族自治区卫生厅自筹经费科研项目(项目编号:Z-2012578)
摘    要:
尿激酶型纤溶酶原激活物与尿激酶型纤溶酶原激活物受体(uPAR)组成的纤溶系统调节纤溶酶原的活化过程,可参与细胞的黏附、转移及血管新生,可溶性尿激酶型纤溶酶原激活物受体是uPAR的可溶形式,缺乏糖基磷脂酰肌醇锚链结构,在肿瘤患者中高表达,有助于判断肿瘤患者的恶性程度及预后,为探讨肿瘤的治疗提供新途径。在多发性骨髓瘤中,其可通过参与骨基质的降解,刺激破骨细胞的增殖等发挥作用。

关 键 词:可溶性尿激酶型纤溶酶原激活物受体  多发性骨髓瘤  预后

Research Progress of Soluble Urokinase-type Plasminogen Activator Receptor and Prognosis of Multiple Myeloma
HUANG Yan-ping,HUANG Jin-xiong. Research Progress of Soluble Urokinase-type Plasminogen Activator Receptor and Prognosis of Multiple Myeloma[J]. Medical Recapitulate, 2013, 19(9): 1584-1586
Authors:HUANG Yan-ping  HUANG Jin-xiong
Affiliation:.(Department of Hematology,People′s Hospital of Liuzhou,Liuzhou 545006,China)
Abstract:
Fibrinolysis system composed by the urokinase-type plasminogen activator and the urokinase-type plasminogen activator recptor(uPAR) regulates the active process of plasminogen,participates in cell adhesion,migration and neovasculization,soluble urokinase-type plasminogen activator receptor is a soluble form of uPAR,lack of glycosyl-phosphatidylinositol anchor domain,which is highly expressed in malignant tumors,and is helpful to distinguish the grade of malignancy and prognosis,and provide some new paths for the treatment.In multiple myeloma,uPAR participates in bone matrix degradation,timulates the proliferation of osteoclasts and so on.
Keywords:Soluble urokinase-type plasminogen activator receptor  Multiple myeloma  Prognosis
本文献已被 CNKI 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号